Temozolomide in the treatment of recurrent malignant glioma
Open accessAbstract
BACKGROUND: Options for chemotherapy at the time of recurrence in patients with malignant glioma are limited. The authors describe the efficacy and safety results of their institution's open‐label, compassionate‐use protocol of temozolomide for patients with recurrent malignant glioma. METHODS: Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose pf 150 mg/m 2 per day on a 5‐day schedule every 28 days. If this dose was tolerated, then escalation to 200 mg/m 2 was allowed. Clinical evaluations and assessments of tumor response were performed every 2 months. All patients or their surrogates signed approved Institutional Review Board consent forms. RESULTS: Among 213 patients who were treated, 33% had Grade 3 tumors, and 67% had Grade 4 tumors. The overall objective response rate was 16% in both of these patient groups; and an additional 51% and 30% of patients with Grade 3 and Grade 4 tumors, respectively, had stable disease as their best response. The 6‐month progression‐free survival rates were 41% and 18% for patients with Grade 3 and Grade 4 tumors, respectively. The median survival was 49 weeks for patients with Grade 3 tumors and 32 weeks for patients with Grade 4 tumors. The major toxicity was hematologic toxicity. In multivariate analysis, the Karnofsky performance score was a significant predictor of survival for patients with Grade 4 tumors. CONCLUSIONS: Temozolomide was well tolerated in patients with recurrent malignant glioma and had modest efficacy, even at the time of multiple recurrences. Cancer 2004. © 2003 American Cancer Society.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The average historical PFS6 based on the above studies is 15.3 ± 3.8%.
“The average historical PFS6 based on the above studies is 15.3 ± 3.8%”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [27]
The average historical TTP is 9.5 ± 1.6 weeks.
“and the average historical TTP is 9.5 ± 1.6 weeks.”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [27]
The average historical OS is 29.3 ± 6 weeks.
“OS averaged 29.3 ± 6 weeks (see SI Table 2).”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [27]
Efficacy analysis was performed for 10 recurrent GBM patients by comparing TTP, PFS6, and OS in recurrent GBM patients treated with the NovoTTF-100A device with the TTP, PFS6, and OS of recurrent GBM patients in a literature based historical control group.
“Efficacy analysis was performed for 10 recurrent GBM patients by comparing TTP, PFS6, and OS in recurrent GBM patients treated with the NovoTTF-100A device with the TTP, PFS6, and OS of recurrent GBM patients in a literature based historical control group (10, 25–28).”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Walker, M. D., Alexander, E., Hunt, W., Maccarty, C. S., Mahaley, M., Mealey, J., Norrell, H., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,751 · see citing works
Walker, M. D., Green, S. B., Byar, D., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W., Maccarty, C. S., Mahaley, M., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,727 · see citing works
Curran, W. J., Scott, C., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C., Rotman, M., Asbell, S., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,309 · see citing works
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 3× · see citing works
“4 weeks and 60% reported by the trial of temozolomide for patients with GM at first recurrence.(11) The combined response and disease stabilization rate of 55% among patients in the current study with Grade 4 lesions also was similar to the 63% rate reported in a smaller study of temozolomide in patients with newly di…”
BackgroundResultSelf-citationStupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1375 · Cited by 857 · see citing works
Yung, W. K. A., Prados, M. D., Yayá, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R. E., Olson, J. J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 756 · see citing works
Self-citationChang, C. H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Krämer, S., Weinstein, A. S., Nelson, J. S., & Tsukada, Y. (1983) · Cancer · doi:10.1002/1097-0142(19830915)52:6 · Cited by 598 · see citing works
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E. S., Blackledge, G. R. P., Slack, J., Rustin, G. J. S., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M. F. G., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488 · see citing works
Kristiansen, K., Hagen, S., Kollevold, T., TORVIK, A., Holme, I., Stat, M. A., Nesbakken, R., Hatlevoll, R., Lindgren, M., Brun, A., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810215)47:4 · Cited by 424 · see citing works
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M. H., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423 · see citing works
Bleehen, N. M., & Stenning, S. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.396 · Cited by 415 · see citing works
Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8 · Cited by 413 · see citing works
Sb, G., Byar, D. P., Walker, Pistenmaa, D. A., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., Mealey, J., Gl, O., et al. (1983) · PubMed · Cited by 404 · see citing works
Levin, V. A., Silver, P., Hannigan, J. F., Wara, W. M., Gutin, P. H., Davis, R. L., & Wilson, C. B. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90096-3 · Cited by 400 · see citing works
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 355 · see citing works
O'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Christopher Kennard, C., Colquhoun, I. R., Lewis, P. D., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 275 · see citing works
Groves, M. D., Puduvalli, V. K., Hess, K. R., Jaeckle, K. A., Peterson, P., Yung, W. K. A., & Levin, V. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1383 · Cited by 229 · see citing works
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Bower, M., Newlands, E. S., Bleehen, N. M., Brada, M., Beǵent, R. H. J., Calvert, H., Colquhoun, I. R., Lewis, P., & Brampton, M. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050691 · Cited by 218 · see citing works
Intravenous carboplatin for recurrent malignant glioma: a phase II study.
Yung, W. K. A., Mechtler, L., & Gleason, M. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.860 · Cited by 180 · see citing works
Groves, M. D., Puduvalli, V. K., Hess, K. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1383 · Cited by 118 · see citing works
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B., Raizer, J. J., Malkin, M. G., Bazylewicz, K. A., & Abrey, L. E. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.1.39 · Cited by 107 · see citing works
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-1-39 · Cited by 85 · see citing works
Newton, H. B., Junck, L., Bromberg, J., Page, M. A., & Greenberg, H. S. (1990) · Neurology · doi:10.1212/wnl.40.11.1743 · Cited by 78 · see citing works
Self-citationPorschen, R., Lohe, B., Hengels, K. J., & Borchard, F. (1989) · Cancer · doi:10.1002/1097-0142(19891215)64:12 · Cited by 75 · see citing works
Self-citationTemozolomide in malignant gliomas.
Yung, W. K. A. (2000) · PubMed · Cited by 63 · see citing works
Brandes, A. A., Ermani, M., Basso, U., Paris, M. K., Lumachi, F., Berti, F., Amistà, P., Gardiman, M. P., Iuzzolino, P., Turazzi, S., et al. (2002) · Oncology · doi:10.1159/000065718 · Cited by 59 · see citing works
New chemotherapy options for the treatment of malignant gliomas
Burton, E. M., & Prados, M. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199905000-00003 · Cited by 57 · see citing works
Self-citationPhase II Trial with BCNU plus α-Interferon in Patients with Recurrent High-Grade Gliomas
Brandes, A. A., Scelzi, E., Zampieri, P., Rigon, A., Rotilio, A., Amistà, P., Berti, F., & Fiorentino, M. V. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199708000-00008 · Cited by 41 · see citing works
Temozolomide as Second-line Chemotherapy for Relapsed Gliomas
Trent, S., Kong, A. H., Short, S. C., Traish, D., Ashley, S., Dowe, A., Hines, F., & Brada, M. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1015788814667 · Cited by 31 · see citing works
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Hs, F. (2000) · PubMed · Cited by 29 · see citing works
Galanis, E., Buckner, J. C., Burch, P. A., Schaefer, P. L., Dinapoli, R. P., Novotny, P. J., Scheithauer, B. W., Rowland, K. M., Vukov, A. M., Mailliard, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2953 · Cited by 29 · see citing works
Combined Intra-arterial and Systemic Chemotherapy for Recurrent Malignant Brain Tumors
Watne, K., Hannisdal, E., Nome, O., Hager, B., & Hirschberg, H. (1992) · Neurosurgery · doi:10.1227/00006123-199202000-00012 · Cited by 25 · see citing works
Hildebrand, J. G., Witte, O. D., & Sahmoud, T. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005952925378 · Cited by 25 · see citing works
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study
Hochberg, F. H., Prados, M., Russell, C. A., Weissman, D., Evans, R. G., Cook, P., Burton, G. V., Eisenberg, P. D., Valenzuela, R. F., & Verkh, L. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005727204169 · Cited by 20 · see citing works
Self-citationIntravenous BCNU and AZQ in patients with recurrent malignant gliomas
Yung, W. K. A., Harris, M., Bruner, J. M., & Feun, L. G. (1989) · Journal of Neuro-Oncology · doi:10.1007/bf00172916 · Cited by 20 · see citing works
Combined Intra-arterial and Systemic Chemotherapy for Recurrent Malignant Brain Tumors
Watne, K., Hannisdal, E., Nome, O., Hager, B., & Hirschberg, H. (1992) · Neurosurgery · doi:10.1097/00006123-199202000-00012 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radia- tion therapy with and without adjuvant chemotherapy for malignant gliomas in adults [see comments]. Cancer. 1993; 71:2585-2597.
- Rodriguez LA, Prados M, Silver P, et al. Reevaluation of procarbazine for the treatment of recurrent malignant cen- tral nervous system tumors. Cancer. 1989;64:2420 -2423.
Cited by
Sorted by citations
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894 · see citing works
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862 · see citing works
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K. V., Boni, J. P., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 690 · see citing works
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518 · see citing works
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433 · see citing works
Grosu, A., Weber, W., Franz, M. A., Stärk, S., Piert, M., Thamm, R., Gumprecht, H., Schwaiger, M., Molls, M., & Nieder, C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.01.056 · Cited by 374 · see citing works
Paz, M. F., Yayá, R., Rojas-Marcos, I., Reynés, G., Pollán, M., Aguirre‐Cruz, L., García-Lopez, J. L., Piquer, J., Safont, M. J., Balañá, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0392 · Cited by 260 · see citing works
Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F. J., Jauch, T., Steinbrecher, A., Brawanski, A. T., Proescholdt, M. A., Schlaier, J. R., Buchroithner, J., et al. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0053 · Cited by 215 · see citing works
Optimal role of temozolomide in the treatment of malignant gliomas
Stupp, R., van den Bent, M. J., & Hegi, M. E. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0047-7 · Cited by 205 · see citing works
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195 · see citing works
The role of imaging in the management of progressive glioblastoma
Ryken, T. C., Aygün, N., Morris, J., Schweizer, M. L., Nair, R., Spracklen, C. N., Kalkanis, S. N., & Olson, J. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1330-0 · Cited by 196 · see citing works
FIVE-AMINOLEVULINIC ACID FOR FLUORESCENCE-GUIDED RESECTION OF RECURRENT MALIGNANT GLIOMAS
Nabavi, A., Thurm, H. C., Zountsas, B., Pietsch, T., Lanfermann, H., Pichlmeier, U., & Mehdorn, H. M. (2009) · Neurosurgery · doi:10.1227/01.neu.0000360128.03597.c7 · Cited by 194 · see citing works
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas
Galldiks, N., Kracht, L., Burghaus, L., Thomas, A., Jacobs, A. H., Heiss, W., & Herholz, K. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0002-5 · Cited by 139 · see citing works
Saito, N., Fu, J., Zheng, S., Yao, J., Wang, S., Liu, D. D., Yuan, Y., Sulman, E. P., Lang, F. F., Colman, H., et al. (2013) · Stem Cells · doi:10.1002/stem.1528 · Cited by 133 · see citing works
How effective is BCNU in recurrent glioblastoma in the modern era?
Brandes, A. A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., & Ermani, M. (2004) · Neurology · doi:10.1212/01.wnl.0000140495.33615.ca · Cited by 131 · see citing works
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
Nieder, C., Adam, M. F., Molls, M., & Grosu, A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.007 · Cited by 110 · see citing works
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4225-7 · Cited by 109 · see citing works
Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4015-2 · Cited by 108 · see citing works
Nieder, C., Astner, S. T., Mehta, M. P., Grosu, A., & Molls, M. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815e3fdc · Cited by 104 · see citing works
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells
Sunayama, J., Satō, A., Matsuda, K., Tachibana, K., Suzuki, K., Narita, Y., Shibui, S., Sakurada, K., Kayama, T., Tomiyama, A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq103 · Cited by 101 · see citing works
Dose‐dense temozolomide regimens
Neyns, B., Tosoni, A., Hwu, W., & Reardon, D. A. (2010) · Cancer · doi:10.1002/cncr.25035 · Cited by 98 · see citing works
Schlingensiepen, K., Fischer-Blass, B., Schmaus, S., & Ludwig, S. (2007) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-71279-4_16 · Cited by 86 · see citing works
Li, B., Xiao, H. P., Cai, M., Li, M., Xu, X., Wang, S., Huang, S. Q., Wang, Y., Cheng, D., Pang, P., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909117 · Cited by 66 · see citing works
Jungk, C., Chatziaslanidou, D., Ahmadi, R., Capper, D., Bermejo, J. L., Exner, J., von Deimling, A., Herold‐Mende, C. C., & Unterberg, A. W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2131-6 · Cited by 62 · see citing works
The efficacy of temozolomide for recurrent glioblastoma multiforme
Chen, C., Xu, T., Lu, Y., Chen, J., & Wu, S. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03778.x · Cited by 58 · see citing works
Li, B., Chen, G., Zhong, H., Li, T., Lin, M., Wei, H., Zhang, Q., Chen, Q., Huang, J., & Shuai, X. (2024) · Nature Communications · doi:10.1038/s41467-024-54382-z · Cited by 50 · see citing works
Yamini, B., Yu, X., Gillespie, G. Y., Kufe, D. W., & Weichselbaum, R. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2117 · Cited by 48 · see citing works
Guiu, S., Taillibert, S., Chinot, O. L., Taillandier, L., Honnorat, J., Dietrich, P., Maire, J.-P., Guillamo, J., Guiu, B., Catry‐Thomas, I., et al. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2008.04.003 · Cited by 47 · see citing works
The role of cytotoxic chemotherapy in the management of progressive glioblastoma
Olson, J. J., Nayak, L., Ormond, D. R., Wen, P. Y., & Kalkanis, S. N. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1338-5 · Cited by 45 · see citing works
Zong, Z., Hua, L., Wang, Z., Xu, H., Ye, C., Pan, B., Zhao, Z., Zhang, L., Lu, J. L., Liu, H., et al. (2019) · Drug Delivery · doi:10.1080/10717544.2018.1534897 · Cited by 45 · see citing works
Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
McDuff, S. G. R., Dietrich, J., Atkins, K. M., Oh, K. S., Loeffler, J. S., & Shih, H. A. (2019) · Cancer Medicine · doi:10.1002/cam4.2686 · Cited by 42 · see citing works
Pulsed reduced dose-rate radiotherapy: case report
Cannon, G. M., Tomé, W. A., Robins, H. I., & Howard, S. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9329-z · Cited by 42 · see citing works
Imaging Stem Cell Implant for Cellular-Based Therapies
Lee, Z., Dennis, J. E., & Gerson, S. L. (2008) · Experimental Biology and Medicine · doi:10.3181/0709-mr-234 · Cited by 40 · see citing works
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway
Jiang, C. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.674 · Cited by 39 · see citing works
Turriziani, M., Caporaso, P., Bonmassar, L., Buccisano, F., Amadori, S., Venditti, A., Cantonetti, M., D’Atri, S., & Bonmassar, E. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2005.12.001 · Cited by 39 · see citing works
Neyns, B., Chaskis, C., Joosens, E. J., Menten, J. J., D'Hondt, L. A., Branle, F., Sadones, J., & Michotte, A. (2008) · Cancer Investigation · doi:10.1080/07357900701708393 · Cited by 39 · see citing works
Shen, C. J., Kummerlowe, M. N., Redmond, K. J., Martínez-Gutiérrez, J. C., Usama, S. M., Holdhoff, M., Grossman, S. A., Laterra, J., Strowd, R. E., III, & Kleinberg, L. R. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.06.005 · Cited by 38 · see citing works
Kang, S., Lee, J. M., Jeon, B., Elkamhawy, A., Paik, S., Hong, J., Oh, S., Paek, S. H., Lee, C. J., Hassan, A. H. E., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.055 · Cited by 35 · see citing works
Uckun, F. M., Qazi, S., Hwang, L., & Trieu, V. N. (2019) · Cancers · doi:10.3390/cancers11121892 · Cited by 35 · see citing works
Saito, N., Aoki, K., Hirai, N., Fujita, S., Iwama, J., Hiramoto, Y., Ishii, M., Sato, K., Nakayama, H., Harashina, J., et al. (2015) · Brain Tumor Pathology · doi:10.1007/s10014-015-0215-7 · Cited by 34 · see citing works
Wei, W., Chen, X., Ma, X., Wang, D., & Guo, Z. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1920-0 · Cited by 34 · see citing works
Tyler, B., Wadsworth, S., Recinos, V. R., Mehta, V., Vellimana, A. K., Li, K., Rosenblatt, J. M., Do, H., Gallia, G. L., Siu, I., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor050 · Cited by 34 · see citing works
Drug screening study using glioma stem-like cells
Feng, X., Zhou, Q., Liu, C., & Tao, M.-L. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1040 · Cited by 33 · see citing works
Pegylated Liposomal Doxorubicin in Recurrent Malignant Glioma: Analysis of a Case Series
Glas, M., Koch, H. J., Hirschmann, B., Jauch, T., Steinbrecher, A., Herrlinger, U., Bogdahn, U., & Hau, P. (2007) · Oncology · doi:10.1159/000113052 · Cited by 33 · see citing works
Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects
Robins, H. I., Lassman, A. B., & Khuntia, D. (2009) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2009.08.015 · Cited by 29 · see citing works
Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma
Ruiz-Garcia, H. J., Ramírez-Loera, C., Malouff, T. D., Seneviratne, D. S., Palmer, J. D., & Trifiletti, D. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189673 · Cited by 28 · see citing works
Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Nieder, C., Adam, M. F., & Grosu, A. (2006) · Reviews on Recent Clinical Trials · doi:10.2174/157488706775246148 · Cited by 22 · see citing works
Galanis, E., Buckner, J. C., Maurer, M. J., Reid, J. M., Kuffel, M. J., Ames, M. M., Scheithauer, B. W., Hammack, J. E., Pipoly, G., & Kuross, S. A. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2910-4 · Cited by 22 · see citing works
Sanctis, V. D., Mazzarella, G., Osti, M. F., Valeriani, M., Alfò, M., Salvati, M., Banelli, E., Tombolini, V., & Enrici, R. M. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224446.31577.df · Cited by 20 · see citing works
Caporaso, P., Turriziani, M., Venditti, A., Marchesi, F., Buccisano, F., Tirindelli, M. C., Alvino, E., Garbin, A., Tortorelli, G., Toppo, L., et al. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.016 · Cited by 19 · see citing works
Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging
Soni, V. S., & Yanagihara, T. K. (2019) · Cancer Imaging · doi:10.1186/s40644-019-0259-8 · Cited by 19 · see citing works
Recent therapeutic advances and insights of recurrent glioblastoma multiforme
Chen, J. (2012) · Frontiers in bioscience · doi:10.2741/4130 · Cited by 18 · see citing works
Li, X., Shang, X., Liu, J., Zhang, Y., Jia, X., Li, H., Wang, Y., Gao, J., Ma, X., Zhang, X. H., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68112-6 · Cited by 15 · see citing works
Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates
Li, Q., Aishwarya, S., Li, J.-P., Pan, D., & Shi, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.832742 · Cited by 15 · see citing works
Everaert, E. G., Neyns, B., Joosens, E. J., Strauven, T., Branle, F., & Menten, J. J. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000040809.97943.c0 · Cited by 14 · see citing works
Li, R., Tang, D., Zhang, J., Wu, J., Wang, L., & Dong, J. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1255-7 · Cited by 14 · see citing works
Shah, G., Silver, J. S., Rosenfeld, S. S., Gavrilovic, I. T., Abrey, L. E., & Lassman, A. B. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9408-1 · Cited by 14 · see citing works
Lin, C., Lin, X., Lin, L., Wang, J.-M., Lin, Z.-X., & Lin, J.-M. (2015) · Chinese Chemical Letters · doi:10.1016/j.cclet.2015.03.007 · Cited by 13 · see citing works
Resection and Immunotherapy for Recurrent Grade III Glioma
Elens, I., Vleeschouwer, S. D., Pauwels, F., & Gool, S. V. (2012) · ISRN Immunology · doi:10.5402/2012/530179 · Cited by 12 · see citing works
Goldim, J. R. (2008) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892008000300007 · Cited by 12 · see citing works
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.
Diedrich, A., Bock, H. C., König, F. B., Schulz, T., Ludwig, H. C., Herken, R., & Quondamatteo, F. (2006) · PubMed · doi:10.14670/hh-21.1199 · Cited by 11 · see citing works
Ashby, L. S., Troester, M. M., & Shapiro, W. R. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.06.005 · Cited by 11 · see citing works
Cystemustine in recurrent high grade glioma
Durando, X., Thivat, É., Roche, H. H., Bay, J., Lemaire, J., Verrelle, P., Lentz, M.-A., Chazal, J., Curé, H., & Chollet, P. J. M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9096-7 · Cited by 10 · see citing works
Saito, N., Hirai, N., Aoki, K., Sato, S., Suzuki, R., Hiramoto, Y., Fujita, S., Nakayama, H., Hayashi, M., Sakurai, T., et al. (2019) · Cancers · doi:10.3390/cancers11101564 · Cited by 10 · see citing works
Chemotherapy of High-Grade Astrocytomas
Newton, H. B. (2006) · Elsevier eBooks · doi:10.1016/b978-012088410-0/50062-7 · Cited by 8 · see citing works
Management of Temozolomide Toxicity by Nurse Practitioners in Neuro-Oncology
Zwinkels, H., Roon, K. I., Jeurissen, F. J. F., TAPHOORN, M. J. B., Hop, W. C. J., & Vecht, C. J. (2009) · Oncology nursing forum · doi:10.1188/09.onf.225-231 · Cited by 7 · see citing works
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia
Mabasa, V. H., & Taylor, S. C. M. (2006) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155206069161 · Cited by 7 · see citing works
Glioblastoma Multiforme—Past, Present, and Future
Lassman, A. B., & Holland, E. C. (2006) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2006.00.00.1k · Cited by 7 · see citing works
Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future
Cavaliere, R., & Newton, H. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.749 · Cited by 5 · see citing works
Motomura, K., Natsume, A., & Wakabayashi, T. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0651-0 · Cited by 4 · see citing works
Greanya, E., Taylor, S., BscPharm, F. H., Barnett, J., & Thiessen, B. A. (2004) · Journal of Oncology Pharmacy Practice · doi:10.1191/1078155204jp138oa · Cited by 4 · see citing works
Baehring, J. M. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-5961-z · Cited by 3 · see citing works
Donahue, B. R. (2008) · Medical radiology · doi:10.1007/978-3-540-77385-6_33 · Cited by 2 · see citing works
Hegde, M. M., Goda, J. S., Mutalik, S., Palkar, P., Mohanty, B. S., Chaudhari, P. R., Sahay, A., Thorat, R. A., Parashiva, G. K., & Rao, B. S. S. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00797-9 · Cited by 1 · see citing works
Locoregional Treatment of Brain Tumors
Kunikowska, J., Morgenstern, A., Bruchertseifer, F., & Królicki, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-63067-0_35 · Cited by 1 · see citing works
TEMOZOLOMIDE IN MALIGNANT ASTROCYTIC GLIOMAS
Borisov, K. E., & Sakayeva, D. D. (2012) · Russian Journal of Oncology · doi:10.17816/onco39963 · Cited by 1 · see citing works
Zhang, S., Xu, L., Chen, G., Wang, Q., Hu, X., Wen, N., Liu, X., Peng, X., Fan, L., Guo, B., et al. (2019) · Research Square · doi:10.21203/rs.2.10495/v1 · Cited by 1 · see citing works
Applications in Malignant Brain Tumors
Nieder, C., & Gilbert, M. R. (2006) · Springer eBooks · doi:10.1007/3-540-35662-2_12 · Cited by 1 · see citing works
Manejo de los tumores hipofisarios agresivos
Aller, J., Michelena, M. C., García, N. P., & García, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-538-7.00011-3
Chemoradiotherapy: Radiation Total Dose and Fractionation
Chiesa, S., Balducci, M., Ferro, M., Alitto, A. R., & Valentini, V. (2016) · Current clinical pathology · doi:10.1007/978-3-319-28305-0_4
Christopher Nicholson BA (Hons), M. (. N. (2007) · Heart failure · doi:10.1002/9780470988107.refs
Brandes, A. A., & Franceschi, E. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1927958.1482056
Zhang, S., Xu, L., Chen, G., Liu, J., Wang, Q., Hu, X., Wen, N., Liu, X., Peng, X., Fan, L., et al. (2019) · Research Square · doi:10.21203/rs.2.10495/v3
Baehring, J. M. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000024311.49169.33
MPhil, P. J. G. (2007) · Wiley eBooks · doi:10.1002/9780470988121.refs
Kerboua, E., Hannachi, K., Mazouzi, C., & Benyahia, R. (2023) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2023.1(1).08
Antikonvulsive Therapie bei Patienten mit Gliomen
Menn, O. (2006)
Promising efficacy of teniposide in H3K27M mutant diffuse midline gliomas: a case report
Wang, X., Niu, T., Xia, J., Liu, J., & Sun, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1784250
- Authors
- Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., & Prados, M. D.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Chang, Susan M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-01-20
- Volume
- 100
- Issue
- 3
- Pages
- 605-611
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1974210709
- Cited by
- 90
- References
- 35
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 7 · 2018: 5 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 6
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- temozolomide, recurrent malignant glioma, glioblastoma, chemotherapy, oral chemotherapy, progression-free survival, objective response rate, hematologic toxicity, Karnofsky performance status, survival predictors
- MeSH terms
- Temozolomide, Adolescent, Adult, Aged, Biopsy, Needle, Brain Neoplasms, Dacarbazine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Glioma, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Probability, Multivariate Analysis, Proportional Hazards Models, Survival Analysis, Treatment Outcome, Risk Assessment, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
